List of Excipients in Branded Drug ERYTHROMYCIN BASE FILMTAB

Generic Drugs Containing ERYTHROMYCIN BASE FILMTAB

Company	Ingredient	NDC	Excipient
Rebel Distributors Corp	erythromycin	21695-387	CELLULOSE, MICROCRYSTALLINE
Rebel Distributors Corp	erythromycin	21695-387	CROSCARMELLOSE SODIUM
Rebel Distributors Corp	erythromycin	21695-387	CROSPOVIDONE

What are the Most Frequently-Used Excipients in ERYTHROMYCIN BASE FILMTAB?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	CROSCARMELLOSE SODIUM
1	CROSPOVIDONE

Erythromycin Base Filmtab Excipient Strategy and Commercial Opportunities

Last updated: August 3, 2026

Erythromycin Base Filmtab is an immediate-release, film-coated oral dosage form of erythromycin base. Its primary formulation challenge is acid instability in the stomach, not API novelty. The commercial opportunity is therefore concentrated in gastroprotection, dose uniformity, swallowability, supply reliability, and differentiated packaging rather than patent exclusivity.

Erythromycin base is a mature macrolide antibiotic with extensive generic competition. A new product would need to compete on manufacturing cost, regulatory simplicity, tablet performance, shortage resilience, and targeted distribution. An excipient strategy based on enteric protection, low-cost coating technology, and robust dissolution control offers the clearest route to differentiation.

What is Erythromycin Base Filmtab?

Erythromycin Base Filmtab is a film-coated tablet containing erythromycin base, generally marketed in 250-mg and 500-mg strengths. The product is administered orally for susceptible bacterial infections and has historically been used when a macrolide alternative to penicillin is required.

The formulation is distinct from erythromycin estolate, ethylsuccinate, and stearate. Those salts or esters alter taste, tolerability, dissolution, pharmacokinetics, and manufacturing characteristics. Erythromycin base is poorly stable under acidic conditions, creating a formulation requirement for protection from gastric fluid.

What dosage forms compete with Erythromycin Base Filmtab?

Product category	Active form	Primary formulation issue	Commercial implication
Erythromycin base tablet	Erythromycin base	Gastric acid instability	Requires acid protection or a validated protective matrix
Erythromycin ethylsuccinate suspension/tablet	Erythromycin ethylsuccinate	Taste, suspension stability, pediatric dosing	Stronger pediatric positioning
Erythromycin stearate tablet	Erythromycin stearate	Dissolution and food effects	Alternative solid oral product
Azithromycin tablet	Azithromycin	Macrolide resistance and class competition	Convenient short-course competitor
Clarithromycin tablet	Clarithromycin	Drug interactions and resistance	Broad adult outpatient competitor

The most direct generic competition comes from other erythromycin oral products, while the broader commercial competition comes from azithromycin and clarithromycin.

What excipients are used in Erythromycin Base Filmtab?

The excipient composition depends on the manufacturer, strength, manufacturing site, and regulatory filing. Historical film-coated erythromycin base tablets have used conventional tablet excipients, including diluents, binders, disintegrants, lubricants, coating polymers, pigments, and opacifiers.

Common excipient functions include:

Excipient function	Typical materials	Role in erythromycin base tablets
Diluent	Lactose, microcrystalline cellulose, starch	Controls tablet weight and compressibility
Binder	Povidone, pregelatinized starch, hypromellose	Improves granule and tablet strength
Disintegrant	Crospovidone, sodium starch glycolate, croscarmellose sodium	Promotes release after protective coating rupture
Lubricant	Magnesium stearate, stearic acid	Reduces tooling adhesion and ejection force
Film former	Hypromellose or methacrylic acid copolymer	Provides cosmetic or enteric protection
Plasticizer	Polyethylene glycol, triethyl citrate	Reduces coating brittleness
Opacifier and colorant	Titanium dioxide, iron oxides, approved dyes	Supports appearance and light protection
Anti-tacking agent	Talc	Improves coating-process performance

A commercial development program should not treat the inactive-ingredient list as interchangeable. Erythromycin base can be sensitive to microenvironmental pH, moisture, heat, and coating-process conditions. Each excipient should be assessed for chemical compatibility, impact on dissolution, and extractables or leachables risk.

What formulation strategy best protects erythromycin base?

The preferred formulation strategy is an acid-resistant tablet with rapid release after gastric transit. A conventional cosmetic film coat is unlikely to provide adequate protection unless the core and coating system are specifically validated for gastric resistance.

Enteric coating strategy

An enteric coating can use a pH-dependent polymer such as:

• Methacrylic acid-ethyl acrylate copolymer
• Methacrylic acid-methyl methacrylate copolymer
• Cellulose acetate phthalate
• Hypromellose phthalate
• Polyvinyl acetate phthalate

The commercial target is a coating that remains intact in simulated gastric fluid and releases promptly in intestinal conditions. Excessive coating weight can delay release, increase tablet size, raise manufacturing cost, and create dissolution variability.

A practical development range is to screen multiple coating weight gains rather than select a single nominal level early. The final design should be based on acid-stage resistance, buffer-stage release, stability, and scale-up behavior.

Core formulation strategy

The tablet core should balance mechanical strength with rapid post-coating disintegration. Excessive compression force can reduce porosity and slow release. High lubricant concentrations can also impair wetting and dissolution.

A robust core commonly requires:

1. A compressible diluent system.
2. A binder level sufficient to prevent friability.
3. A superdisintegrant that remains effective after coating.
4. A controlled lubricant concentration.
5. Moisture protection during granulation, coating, and packaging.

Direct compression may reduce manufacturing steps, but wet granulation may provide better content uniformity and flow for high-dose erythromycin base. The choice depends on API particle-size distribution, bulk density, dose-to-weight ratio, and segregation behavior.

Taste and swallowability

Taste masking is less important for intact adult tablets than for suspensions or chewable dosage forms. Tablet size remains commercially important because 500-mg products can be large after excipients and enteric coating are added. A smaller, higher-density core or an optimized bilayer design may improve swallowability without changing the labeled dose.

What patents protect Erythromycin Base Filmtab?

Erythromycin base is an old active ingredient, and the original composition-of-matter protection has expired. Current commercial value does not depend on an active compound patent.

IP category	Expected status for erythromycin base	Commercial relevance
Composition-of-matter patent	Expired	No meaningful exclusivity
Basic oral tablet formulation	Generally expired or vulnerable to design-around	Low barrier
Enteric coating formulation	Potentially patentable only if technically distinct and non-obvious	Moderate if supported by superior data
Manufacturing process	Potentially protectable	Moderate operational value
Packaging and stability system	Potentially protectable	Narrow but useful
Method of use	Historical claims largely expired or weak	Limited commercial protection
New indication	Possible only with strong clinical differentiation	Requires substantial evidence

A new patent position would need to focus on a specific formulation, manufacturing process, stability profile, or delivery system. Broad claims covering a film-coated erythromycin tablet would face substantial validity and obviousness risk.

When does Erythromycin Base Filmtab lose exclusivity?

Erythromycin Base Filmtab has no commercially meaningful new-drug exclusivity expected from the active ingredient. Erythromycin was approved decades ago, and the relevant exclusivity periods have expired.

The product’s market access is therefore governed mainly by:

• ANDA approval requirements.
• Current USP monograph compliance.
• Product-specific bioequivalence or comparative dissolution requirements.
• Manufacturing-site compliance.
• Labeling and supply continuity.
• Any surviving formulation or process patents, if listed.

A branded or reformulated product could obtain limited regulatory exclusivity only if it met the requirements for a new drug, new indication, pediatric study, or another qualifying FDA pathway. A conventional generic film-coated tablet would not receive meaningful market exclusivity merely because it uses a different excipient system.

What is the Orange Book status of Erythromycin Base Filmtab?

The Orange Book is the controlling source for current FDA-listed patents, therapeutic-equivalence codes, and reference-listed-drug status. Historical brand products may have been discontinued while generic erythromycin products remain approved under separate ANDAs.

For commercial diligence, the relevant checks are:

Orange Book issue	Assessment
Reference listed drug	Must be confirmed for the specific strength and dosage form
Patent listing	No active compound patent is expected; formulation listings require current verification
Exclusivity	No active original NCE exclusivity is expected
Therapeutic equivalence	Depends on the specific reference product and approved generic
Discontinuation status	Historical products may be listed as discontinued without being withdrawn for safety reasons

A proposed generic must identify the correct reference product for each strength. A product that relies on a discontinued reference product may require a regulatory strategy based on the FDA’s current reference-product framework rather than simple reliance on a commercial brand.

Which companies are challenging Erythromycin Base Filmtab?

Competition is fragmented among generic manufacturers and contract pharmaceutical companies. Market participation can vary by strength, dosage form, supply status, and pharmacy-channel demand.

The competitive set may include:

• Generic manufacturers with approved erythromycin base tablets.
• Companies supplying erythromycin stearate or ethylsuccinate.
• Contract manufacturers producing private-label antibiotic tablets.
• Branded macrolide suppliers competing for outpatient prescriptions.
• Hospital and institutional suppliers responding to shortage conditions.

A reliable company-by-company ranking requires current FDA approval data, product availability, wholesaler listings, and shipment information. The commercial threat is usually price competition rather than patent litigation.

What Paragraph IV challenges affect erythromycin base tablets?

Paragraph IV litigation risk is expected to be limited for a conventional erythromycin base tablet because the relevant active-ingredient patents are old. A Paragraph IV certification could arise if a listed patent covered a specific formulation, coating, manufacturing process, or use.

The likely litigation profile is:

Issue	Risk assessment
Composition-of-matter challenge	Not commercially relevant because protection has expired
Enteric-coating patent	Possible if a current listed patent exists
Process patent	Possible but difficult to enforce against an independently manufactured product
Method-of-use patent	Narrow relevance unless the proposed label overlaps a patented indication
ANDA settlement	Unlikely to be a central market event for legacy erythromycin

Any current patent litigation should be checked in FDA Orange Book listings, Federal Court records, and Paragraph IV notices. No litigation conclusion should be drawn solely from the existence of historical erythromycin patents.

What formulation patents could create commercial value?

A defensible formulation patent would need a narrow technical proposition supported by comparative data. Potential claim areas include:

Acid-protection and dissolution

Claims could cover a specific core-coat combination that produces:

• Defined gastric-stage resistance.
• Rapid intestinal release.
• Reduced batch-to-batch dissolution variability.
• Stability under accelerated conditions.
• Lower coating weight than conventional systems.

Moisture and thermal stability

Erythromycin base products may benefit from claims directed to:

• Low-water-activity excipient systems.
• Desiccant-enabled packaging.
• High-barrier blister packs.
• Specific granulation or drying conditions.
• Stabilizing pH modifiers.

Manufacturing process

A process patent may address:

• API particle-size control.
• Granulation endpoint.
• Coating temperature and spray rate.
• In-line control of coating weight.
• Reduced tablet defects and improved yield.

Process patents are commercially useful when they lower cost or solve a known scale-up problem. They are harder to enforce because the relevant steps may occur inside a competitor’s manufacturing facility.

How strong is the patent estate for Erythromycin Base Filmtab?

The legacy patent estate is weak. A new product would have limited freedom-to-operate exposure from the active ingredient but also limited ability to block generic competitors.

Patent dimension	Strength
Active ingredient	Very weak or expired
Conventional tablet composition	Weak
Enteric coating	Moderate only with narrow, data-supported claims
Stability packaging	Moderate but easy to design around
Manufacturing process	Moderate operational protection
Method of use	Low for legacy indications
Regulatory exclusivity	None expected for a conventional generic

The strongest commercial strategy is likely a combined trade-secret and regulatory approach rather than reliance on a broad patent. Process controls, supplier qualification, coating know-how, and stability data can protect margins even when the public patent estate is limited.

What FDA regulatory pathway applies to a new product?

A conventional generic would generally proceed through an ANDA if an appropriate reference product exists. The filing would need to address the active ingredient, dosage form, strength, labeling, bioequivalence, manufacturing controls, and product quality.

The regulatory program should prioritize:

• Acid-stage and buffer-stage dissolution.
• Comparative dissolution against the reference product.
• Assay and content uniformity.
• Degradation-product control.
• Tablet hardness and friability.
• Microbial controls where relevant.
• Stability in the proposed commercial package.
• Compatibility of coating polymers and colorants with FDA requirements.

A materially different delivery system may require a 505(b)(2) application rather than an ANDA. That route could support differentiated labeling or clinical claims but would increase development cost and regulatory risk.

What commercial opportunities exist for erythromycin base tablets?

The strongest opportunities are operational and market-access driven.

Supply continuity

Erythromycin products have historically faced manufacturing and availability constraints in some markets. A supplier with reliable API sourcing, dual manufacturing sites, and validated alternate excipients could win institutional contracts even without product differentiation.

Institutional packaging

Hospitals, long-term-care facilities, and government buyers may value:

• Unit-dose blister packaging.
• Barcoded cartons.
• Tamper-evident packaging.
• Extended shelf life.
• Reliable 250-mg and 500-mg supply.
• Contract-specific labeling.

Pediatric and specialty formats

Erythromycin base film-coated tablets are less suitable for patients unable to swallow solid dosage forms. A company could develop a complementary portfolio consisting of:

• Smaller tablets.
• Oral suspension.
• Dispersible tablets.
• Taste-masked granules.
• Age-appropriate dosing presentations.

These products would face different formulation and regulatory requirements but could expand the addressable market.

Emerging-market distribution

Price-sensitive markets may favor a low-cost tablet with robust stability under variable temperature and humidity. High-barrier packaging and simplified coating processes can support geographic expansion, provided local registration and quality requirements are met.

How does Erythromycin Base Filmtab compare with azithromycin?

Factor	Erythromycin base	Azithromycin
Patent position	Legacy, largely expired	More recent historical protection, now broadly generic
Dosing convenience	Typically more frequent	Usually shorter or less frequent regimens
Formulation burden	High acid-instability burden	Lower relative burden for standard tablets
Drug interactions	Clinically significant interaction potential	Generally lower interaction burden
Generic price pressure	High	High
Differentiation opportunity	Excipient, stability, supply	Dosing, formulation, adherence
Clinical positioning	Established but less convenient	Strong outpatient convenience

Erythromycin base can remain commercially viable where price, formulary status, pregnancy-related prescribing considerations, or macrolide substitution patterns support demand. It is less attractive as a premium product without a clear formulation or supply advantage.

What generic launch scenarios exist?

Low-cost ANDA launch

This approach uses conventional excipients, standard enteric protection, and commodity packaging. It offers the lowest development cost but exposes the product to rapid price erosion.

Premium reliability launch

This strategy emphasizes dual sourcing, high-barrier packaging, extended dating, and institutional supply contracts. The product may command better margins without requiring a novel clinical claim.

Differentiated formulation launch

A 505(b)(2) or patent-backed formulation could target improved stability, reduced tablet burden, or modified release. This requires stronger development evidence and carries greater regulatory risk.

Portfolio launch

A supplier could combine 250-mg and 500-mg tablets with suspension or dispersible products. This approach improves account coverage and reduces dependence on a single dosage form.

What manufacturing and IP barriers matter most?

The largest barriers are not patent barriers. They are:

• Consistent API quality and particle-size control.
• Reliable acid-stage dissolution.
• Coating uniformity at commercial scale.
• Moisture protection.
• Supplier qualification for polymers and colorants.
• Stability across climatic zones.
• Avoidance of tablet defects during coating and packaging.
• FDA inspection readiness.
• Maintaining supply during API or excipient shortages.

An integrated control strategy can create meaningful commercial separation even when competitors can legally manufacture the same active ingredient.

Key Takeaways

• Erythromycin Base Filmtab is a mature, genericized oral macrolide product.
• The central formulation issue is acid instability, making protective coating and dissolution control critical.
• Conventional excipients provide limited differentiation and little patent leverage.
• A commercially useful excipient strategy should optimize acid resistance, rapid intestinal release, stability, tablet size, and manufacturing yield.
• The legacy patent estate is weak; new protection would need to target a narrow formulation, process, packaging, or stability feature.
• Paragraph IV litigation and biosimilar risk are not central issues for this small-molecule product.
• The strongest commercial opportunities are supply reliability, institutional packaging, geographic expansion, and complementary pediatric dosage forms.
• A low-cost ANDA is the simplest route, while a differentiated formulation would likely require a 505(b)(2) strategy and stronger technical evidence.

FAQs About Erythromycin Base Filmtab

Is Erythromycin Base Filmtab enteric-coated?

Erythromycin base requires protection from gastric acid, but the exact coating design depends on the approved manufacturer and product version. A conventional film coat and an enteric coat are not equivalent.

Can lactose be used in an erythromycin base tablet?

Lactose may be used as a diluent if compatibility, stability, dissolution, and patient-labeling requirements are satisfied. The final excipient selection must be validated for the specific API and manufacturing process.

Is erythromycin base subject to biosimilar competition?

No. Erythromycin is a chemically synthesized small-molecule drug. Competing products are generics or alternative macrolide products, not biosimilars.

Can a new erythromycin coating receive patent protection?

Potentially, but protection would depend on novelty, non-obviousness, written description, enablement, and claim scope. A broad claim to an enteric-coated erythromycin tablet would face substantial patentability risk.

Is a 505(b)(2) application necessary for a new erythromycin base tablet?

Not usually for a conventional generic equivalent with an appropriate reference product. A 505(b)(2) pathway becomes more relevant when the product has a materially different formulation, delivery system, dosing regimen, or clinical claim.

References

1. U.S. Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations. FDA.

2. U.S. Food and Drug Administration. (2023). Guidance for industry: ANDAs for certain highly purified synthetic drug substances. FDA.

3. U.S. Food and Drug Administration. (2024). Inactive ingredient database. FDA.

4. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP Convention.

5. U.S. Food and Drug Administration. (2024). Electronic Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

6. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, patent and exclusivity information. FDA.